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Oculocutaneous albinism (OCA) is a genetically heterogeneous group of disorders characterized by absent or
reduced pigmentation of the skin, hair, and eyes. In humans, four genes have been associated with ‘‘classical’’
OCA and another 12 genes with syndromic forms of OCA. To assess the prevalence of different forms of OCA
and different gene mutations among non-Hispanic Caucasian patients, we performed DNA sequence analysis of
the four genes associated with ‘‘classical’’ OCA (TYR, OCA2, TYRP1, SLC45A2), the two principal genes associated
with syndromic OCA (HPS1, HPS4), and a candidate OCA gene (SILV), in 121 unrelated, unselected non-
Hispanic/Latino Caucasian patients carrying the clinical diagnosis of OCA. We identified apparent pathologic
TYR gene mutations in 69% of patients, OCA2 mutations in 18%, SLC45A2 mutations in 6%, and no apparent
pathological mutations in 7% of patients. We found no mutations of TYRP1, HPS1, HPS4, or SILV in any patients.
Although we observed a diversity of mutations for each gene, a relatively small number of different mutant
alleles account for a majority of the total. This study demonstrates that, contrary to long-held clinical lore,
OCA1, not OCA2, is by far the most frequent cause of OCA among Caucasian patients.
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INTRODUCTION
Oculocutaneous albinism (OCA) is a group of recessive
disorders characterized by reduced or absent pigmentation of
the skin, hair, and eyes, with accompanying optic defects that
include low vision, nystagmus, strabismus, and photophobia.
Because of its visually evident phenotype, OCA was one of
the first genetic disorders recognized (Pliny, 1942; Gellius,
1952) and was one of the original disorders suggested by
Garrod (1908) as a likely inborn error of metabolism.
The nosology of OCA has evolved considerably over time,
and now is firmly based on molecular genetic classification.
‘‘Classical’’ OCA can result from mutations in at least four
genes: TYR (OCA1, OMIM (http://www.ncbi.nlm.nih.gov/
sites/entrez?db=OMIM) no. 203100), OCA2 (P; OCA2, OMIM
no. 203200), TYRP1 (OCA3, OMIM no. 203290), and
SLC45A2 (MATP, OCA4; OMIM no. 606574). In addition,
OCA is a phenotypic component of at least three syndromic
disorders: Hermansky–Pudlak syndrome (HPS, OMIM no.
203300), which can result from mutations in eight known
genes, most frequently HPS1 (OMIM *604982) and HPS4
(OMIM *606682); Chediak–Higashi syndrome (CHS, OMIM
no. 214500), which results from mutations in LYST (CHS1,
OMIM *606897); and Griscelli syndrome (GS), which can
result from mutations in three known genes (MYO5A, OMIM
no. 214450; RAB27A, OMIM no. 607624; and MLPH, OMIM
no. 609227). In the mouse, several additional genes are
known with mutant phenotypes similar to human OCA, most
notably Silv (Pmel17, OMIM *155550), which has not yet
been associated with disease in humans.
In addition to locus heterogeneity, a diversity of mutations
has been identified in each of the OCA genes. At least 211
different pathologic gene mutations have been reported
in TYR, 70 in OCA2, 5 in TYRP1, and 26 in SLC45A2
(cf. Albinism Database; http://albinismdb.med.umn.edu/). It
has proved difficult or impossible to distinguish the four forms
of classical OCA on clinical grounds, and even clinical
distinction between ‘‘classical’’ OCA and HPS is difficult in
some cases (Ito et al., 2005; Garrison et al., 2006).
Accordingly, molecular analysis is essential for accurate
diagnosis and genetic counseling.
The prevalences of the different OCA disorders vary
widely among different populations. Among African and
African-American OCA patients, OCA2 and, to a lesser
extent, OCA3 are most frequent (King et al., 2001, 2007; King
and Oetting, 2006). Among Puerto Rican patients, HPS1 and
HPS4 are most frequent. Among Caucasian patients, clinical
lore and genetics textbooks have long held that OCA2 is the
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most frequent form of OCA (King et al., 2001, 2007; King and
Oetting, 2006); however, the original evidence underlying
this assertion is difficult to ascertain. Virtually all published
studies have described molecular analysis of OCA patients on
a gene-by-gene basis, with few systematic analyses of
different genetic causes of OCA in any population, and none
in non-Hispanic Caucasian patients. Thus, it generally has
not been possible to assess either the relative frequencies of
the different forms of OCA or of different gene mutations.
To establish the relative prevalence of different OCA types
and gene mutations among non-Hispanic Caucasian patients,
we carried out extensive DNA sequence analyses of the four
genes associated with ‘‘classical’’ OCA, TYR, OCA2, TYPR1,
SLC45A2, as well as a candidate OCA gene, SILV, in an
unselected series of 121 unrelated non-Hispanic/Latino
Caucasian patients carrying the clinical diagnosis of OCA.
Because differential diagnosis of ‘‘classical’’ OCA and HPS
can be difficult on clinical grounds (Ito et al., 2005; Garrison
et al., 2006), we also sequenced the two most frequent HPS
genes, HPS1 and HPS4. Patients with known autosomal
recessive ocular albinism (AROA), HPS, and CHS were
excluded and, as CHS and GS are readily distinguished
clinically from OCA, we did not sequence the genes
responsible for these disorders. Our results establish that,
contrary to long-held clinical lore, OCA1 is the most frequent
cause of OCA among Caucasian patients.
RESULTS
TYR (OCA1)
We sequenced all five exons of the TYR gene, and adjacent
intron and flanking sequences (Giebel et al., 1991), including
1,555 bp of the 50 promoter region (except for a region of
simple sequence repeats from nt 88549828–88550258), in all
121 patients. Of the total 121 patients, 84 had been referred
with the clinical diagnosis of OCA1; 93% of these diagnoses
were ultimately confirmed by molecular testing (Table 1).
Overall, we identified apparent pathologic TYR mutations in
84 patients (69%). For 79 of these patients, specific clinical
phenotype information was available; 45 carried the clinical
diagnosis of tyrosinase-negative OCA (OCA1A) and 34
carried the clinical diagnosis of OCA1B. However, only
71% of these specific clinical diagnoses were confirmed by
the molecular results.
Among the 84 patients with molecularly proved OCA1, in
71 (85%), we found two TYR mutations, and in 13 (15%), we
found only one; these latter patients presumably carry mutations
within large introns that were not sequenced completely, or
within regulatory sequences distant from the TYR structural
gene. In all patients with only one apparent pathologic TYR
mutation, we also sequenced a conserved 647 bp DNA
segment located 9 kb upstream of the major TYR mRNA 50
start site, which regulates transcription of TYR mRNA and may
represent a locus control region (Regales et al., 2003); however,
we found no apparent mutations in this upstream segment.
As shown in Table 1, altogether, we identified 56 different
TYR mutations, of which eight were novel, one frameshift
(c124delG), and seven missense substitutions: F84V, I123T,
Y149C, Y181C, H202R, P209L, and L288F. In addition, we
observed two missense variants (S192Y, R402Q) that are
common nonpathologic polymorphisms, as well another
variant, P152S, which we previously considered a probable
pathologic mutation (Gershoni-Baruch et al., 1994), but
which now seems more likely to be a rare nonpathologic
polymorphism. Most TYR mutations were observed in the
compound heterozygous state; only IVS2-7T4A, P81L,
D383N, and P406L were observed in true homozygotes.
Considering the 168 mutant alleles among the 84 patients
with OCA1, 13 mutations accounted for 62% of the total. The
T373K variant was most frequent (13.7%), followed by P81L
(8.3%), V275F (7.1%), IVS2-7T4A (6.5%), G446S (5.4%),
R217Q (3.6%), P406L (3.6%), R422Q (3.6%), D383N (2.4%),
D448N (2.4%), G47D (1.8%), 1164delT (1.8%), and R402X
(1.8%); the other 43 mutations were observed only once or
twice. T373K is by far the most frequent OCA1A mutant
allele, followed by P81L, and V275F and IVS2-7T are the
most frequent OCA1B mutant alleles. Genotypically, about
41% of patients have OCA1A and 46% have OCA1B (13% of
patients could not be assigned with certainty), although
clinical distinction between the two may be difficult in
Caucasian patients, particularly those from families with fair
complexion.
OCA2
We sequenced 24 exons of the OCA2 gene (the first of which
is noncoding) and adjacent intron and flanking sequences
(Lee et al., 1995), including 1,280 bp of the 50 promoter
region, in the 34 patients who lacked pathological mutations
of TYR. We did not sequence exon 19, an alternative exon
that contains an in-frame terminator and thus does not
encode a functional OCA2 mRNA (Lee et al., 1995). We
identified apparent pathological mutations in 22 patients
(18%; Table 1). Among these 22 OCA2 patients, one had
Prader–Willi syndrome (PWS) and one Angelman syndrome,
due to de novo deletion of chromosome 15q, and were thus
hemizygous at the OCA2 locus. Most of the other 20 patients
carried the clinical diagnosis of either OCA2 (or ‘‘type II
OCA’’) or OCA1B. Among the 22 OCA2 patients, in 13 we
found two pathologic OCA2 mutations (counting the 15q
deletions in the two PWS/OCA patients), and in 9 patients we
found only one. As shown in Table 1, overall, we identified
10 different pathologic OCA2 mutations, of which one was
novel: a missense substitution (I634N). In addition, we
observed four missense variants (R266W, R305W, R419Q,
and L440F) that are common nonpathologic polymorphisms.
Most OCA2 mutations were observed in the compound
heterozygous state; only G27R and V443I occurred in true
homozygotes, although V443I was observed in the two 15q
hemizygotes with PWS or Angelman syndrome. Considering
the 42 non-PWS/Angelman syndrome deletion alleles among
the 22 patients with OCA2, 3 mutations accounted for over
57% of the total observed. The V443I mutation was most
frequent (28.6%), followed by the novel G27R mutation
(21.4%) and N489D (7.1%); the other six mutations were
observed only once or twice. We considered the possibility
that some of the nine patients in whom we observed only a
single OCA2 mutation might have partial gene deletions of
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Table 1. Gene mutations in 121 unrelated Caucasian patients with presenting diagnosis of OCA
Gene Patient Age
Clinical
diagnosis
Molecular
diagnosis Consanguinity Mutation 1 Mutation 2 Other
TYR 1 4 OCA1A OCA1A  c.1118C4A (T373K) c.1164delT
2 21 OCA1A OCA1A  c.1147G4A (D383N) c.1467insT
3 Adult OCA1A OCA1A  c.1118C4A (T373K) c.338-339delCA
4 27 OCA1A OCA1A  c.232G4T (E78X) c.1336G4A (G446S)
5 17 OCA1A OCA1A  c.1118C4A (T373K) c.1146C4A (N382K)
6 2m OCA1A OCA1A  c.649C4G (R217G) c.1204C4T (R402X)
7 Child OCA1A OCA1A  c.61C4T (P21S) c.1164delT
8 Adult OCA1A OCA1A  c.242C4T (P81L) c.649C4G (R217G)
9 Child OCA1A OCA1A  c.1118C4A (T373K) c.1336G4A (G446S)
10 4 OCA1A OCA1A  c.542A4G (Y181C) c.1118C4A (T373K) TYR: S192Y (H);
SLC45A2: L374F (h)
11 Adult OCA1A OCA1A  c.238T4C (W80R) c.1336G4A (G446S) TYR: R402Q (H)
12 30 OCA1A OCA1A  c.1118C4A (T373K) c.1184G4A (S395N)
13 8 OCA1A OCA1A  c.140G4A (G47D) c.242C4T (P81L)
14 Adult OCA1A OCA1A + c.242C4T (P81L) c.242C4T (P81L)
15 Adult OCA1A OCA1A  c.25delC c.1336G4A (G446S)
16 Adult OCA1A OCA1A  c.1118C4A (T373K) c.1147G4A (D383N)
17 Child OCA1A OCA1A  c.1118C4A (T373K) c.1336G4A (G446S)
18 6m OCA1A OCA1A  c.164G4A (C55Y) c.242C4T (P81L) TYR: S192Y (H);
SLC45A2: L374F (h)
19 5 OCA1A OCA1A  c.446A4G (Y149C) c.1132C4T (Q378X)
20 45 OCA1A OCA1A  c.446A4G (Y149C) c.1118C4A (T373K)
21 6m OCA1A OCA1A  c.1118C4A (T373K) c.1336G4A (G446S)
22 9 OCA1A OCA1A  c.25delC c.650G4A (R217Q)
23 47 OCA1A OCA1A  c.242C4T (P81L) c.649C4T (R217W)
24 Adult OCA1A OCA1A + c.242C4T (P81L) c.242C4T (P81L)
25 Child OCA1A OCA1A + c.242C4T (P81L) c.242C4T (P81L)
26 Adult OCA1A OCA1A  c.619G4A (A206T) c.1204C4T (R402X)
27 29 OCA1A OCA1A  c.1118C4A (T373K) c.572delG TYR: S192Y (H), R402Q
(H); SLC45A2: L374F (h)
28 37 OCA1A, mental
retardation
OCA1A ? c.1147G4A (D383N) c.1147G4A (D383N) Karyotype normal
29 5m OCA OCA1A  c.1118C4A (T373K) c.1204C4T (R402X)
30 10m OCA OCA1A  c.1118C4A (T373K) c.1075C4T (Q359X) TYR: R402Q (H)
31 9 OCA OCA1A  c.286-287insA c.896G4A (R299H)
32 Adult OCA OCA1A  c.613C4A (P205T) c.896G4A (R299H) SLC45A2: L374F (h)
33 8m OCA1B OCA1A  c.346C4T (R116X) c.649delC
34 9 OCA1B OCA1A  c.650G4A (R217Q) c.1336G4A (G446S)
35 4 OCA1A OCA1B  c.823G4T (V275F) c.1118C4A (T373K)
36 2m OCA1A OCA1B  c.1217C4T (P406L) c.1255G4A (G419R) TYR: S192Y (H);
SLC45A2: L374F (h)
37 Child OCA1A OCA1B  c.140G4A (G47D) c.1037-7T4A (IVS2-
7T4A)
38 3 OCA1A OCA1B  c.823G4T (V275F) c.1118C4A (T373K)
39 7 OCA1A OCA1B  c.823G4T (V275F) c.731-732delGT
40 68 OCA1A OCA1B  c.1118C4A (T373K) c.1265G4A (R422Q)
41 69 OCA1A OCA1B  c.605A4G (H202R) c.1342G4A (D448N)
Table 1 continued on following page
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42 3m OCA1A OCA1B  c.1037-7T4A (IVS2-
7T4A)
c.1118C4A (T373K)
43 24 OCA1A OCA1B  c.299C4T (R77W) c.823G4T (V275F)
44 Adult OCA1A OCA1B  c.1265G4A (R422Q) — TYR: R402Q (h);
SLC45A2: L374F (h)
45 6m OCA1B? OCA1B  c.823G4T (V275F) c.1037-7T4A (IVS2-
7T4A)
46 5 OCA1B? OCA1B  c.1209G4T (R403S) c.1342G4A (D448N)
47 4 OCA1B? OCA1B  c.895C4A (R299S) c.1118C4A (T373K) OCA2: R419Q (H)
48 11m OCA1B OCA1A  c.650G4A (R217Q) c.1467insT SLC45A2: L374F (H)
49 41 OCA1B OCA1B  c.1265G4A (R422Q) c.1336G4A (G446S)
50 36 OCA1B OCA1B  c.61C4T (P21S) c.1342G4A (D448N)
51 Adult OCA1B OCA1B  c.823G4T (V275F) c.242C4T (P81L)
52 4 OCA1B OCA1B  c.1037-7T4A (IVS2-
7T4A)
c.880G4A (E294K)
53 7 OCA1B OCA1B  c.1037-7T4A (IVS2-
7T4A)
c.1037-7T4A (IVS2-
7T4A)
54 6m OCA1B OCA1B  c.242C4T (P81L) c.823G4T (V275F)
55 18m OCA1B OCA1B  c.1037-7T4A (IVS2-
7T4A)
c.1168C4G (H390D)
56 26 OCA1B OCA1B  c.242C4T (P81L) c.823G4T (V275F)
57 82 OCA1B OCA1B  c.1063G4C (A355P) c.1342G4A (D448N)
58 23 OCA1B OCA1B  c.1037-7T4A (IVS2-
7T4A)
c.1138T4C (S380P)
59 15m OCA1B OCA1B  c.1A4G (M1V) c.1217C4T (P406L) TYR: S192Y (H);
SLC45A2: L374F (h)
60 17m OCA1B OCA1B  c.650G4A (R217Q) c.823G4T (V275F) TYR: R402Q (H);
SLC45A2: L374F (h)
61 2 OCA1B OCA1B  c.650G4A (R217Q) c.823G4T (V275F) TYR: S192Y (H),
R402Q (H)
62 20 OCA1B OCA1B  c.823G4T (V275F) c.1501insC
63 8 OCA1B OCA1B  c.1037-7T4A (IVS2-
7T4A)
Total deletion of TYR
64 Adult OCA1B OCA1B  c.242C4T (P81L) c.1265G4A (R422Q) TYR: R402Q (H)
65 37 OCA1B OCA1B + c.1217C4T (P406L) c.1217C4T (P406L)
66 70 OCA1B OCA1B  c.1265G4A (R422Q) c.649C4T (R217W)
67 19 OCA1B OCA1B  c.1265G4A (R422Q) c.124delG
68 10m OCA1B OCA1B  c.650G4A (R217Q) c.864A4T (L288F) TYR: R402Q (h);
SLC45A2: L374F (h)
69 8m OCA1B OCA1B  c.1037-7T4A (IVS2-
7T4A)
c.1037-7T4A (IVS2-
7T4A)
SLC45A2: L374F (h)
70 10 OCA1B OCA1B  c.1217C4T (P406L) c.1217C4T (P406L) TYR: c.1063G4C
(A355P), c.1291C4A
(P431T)
71 14m OCA1B OCA1B  c.823G4T (V275F) —
72 10 OCA1B OCA1B  c.1366+4A4G
(IVS4+4A4G)
— TYR: S192Y (H)
73 4 OCA1B,
mental
retardation
OCA1B  c.973A4G (T325A) — TYR: R402Q (H);
karyotype normal
74 3m OCA1A OCA1  c.344-345delGA c.368T4C (I123T)
Table 1 continued on following page
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75 Child OCA1A OCA1  c.140G4A (G47D) — OCA2: R305W (h)
76 12m OCA1A OCA1  c.1118C4A (T373K) — TYR: S192Y (H)
77 14m OCA1A OCA1  c.731-732delGT —
78 6m OCA1A OCA1  c.1118C4A (T373K) — TYR: R402Q (H), S192Y
(h); OCA2: IVS5-19A4G
(H); SLC45A2: L374F (H)
79 10 OCA1A OCA1  c.1118C4A (T373K) — TYR: R402Q (H)
80 Child OCA1A OCA1  c.1164delT — TYR: S192Y (H)
81 12m OCA1B OCA1  c.1118C4A (T373K) — TYR: R402Q (H), S192Y
(h); SLC45A2: L374F (h)
82 9m OCA1B,
mental
retardation
OCA1  c.250T4G (F84V) — TYR: R402Q (H), S192Y
(h); SLC45A2: L374F (h);
karyotype normal
83 28m OCA1B,
mental
retardation
OCA1  c.1336G4A (G446S) —
84 ? OCA OCA1  c.626C4T (P209L) c.1118C4A (T373K) TYR: S192Y (H);
SLC45A2: L374F (h)
OCA2 85 7 OCA2, PWS OCA2  c.1327G4A (V443I) Deletion 15q11.2-q13.1
86 10 OCA2, Angelman
syndrome
OCA2  c.1327G4A (V443I) Deletion 15q11.2-q13
87 8m OCA1B/OCA2 OCA2  c.1327G4A (V443I) c.1465A4G (N489D)
88 12m OCA1B/OCA2 OCA2  c.79G4A (G27R) c.79G4A (G27R) TYR: R402Q (H); OCA2:
L440F (h); HPS4: E229G
(H), V552 M (h), H606Y
(h), Q625H (h)
89 4m OCA1B/OCA2 OCA2  c.1327G4A (V443I) c.2228C4T (P743L) TYR: R402Q (H); TYRP1:
R93H (H)
90 4 OCA2 OCA2  c.1327G4A (V443I) c.2228C4T (P743L)
91 28 OCA2 OCA2  c.79G4A (G27R) c.2207C4T (S736L) OCA2: L440F (H)
92 18 OCA2 OCA2  c.1327G4A (V443I) c.1327G4A (V443I)
93 6 OCA2 OCA2  c.1441G4A (A481T) c.1465A4G (N489D) OCA2: R305W (H)
94 22 OCA2 OCA2  c.79G4A (G27R) c.79G4A (G27R) SLC45A2: L374F (h);
HPS4: E229G (h), L443V
(H), V552 M (h),
H606Y(h), Q625H (h)
95 12m OCA2 OCA2  c.1327G4A (V443I) c.1327G4A (V443I) TYR: R402Q (H);
SLC45A2: L374F (h)
96 5m OCA2 OCA2  c.79G4A (G27R) c.79G4A (G27R) OCA2: L440F (h); HPS4:
E229G (h), V552 M (h),
H606Y (h), Q625H (h)
97 8 OCA2 OCA2/
AROA
 c.1441G4A (A481T) c.1842+1G4T
(IVS17+1G4T)
98 3 OCA2 OCA2  c.482delG — OCA2: R305W (H)
99 5 OCA2 OCA2  c.1327G4A (V443I) — TYR: R402Q (H); OCA2:
R266W (H); HPS4:
E229G (H), V552 M (H),
H606Y (H), Q625H (H)
100 11m OCA2/multiple
congenital
anomalies
OCA2  c.1327G4A (V443I) — TYR: R402Q (H);
SLC45A2: L374F (h);
HPS4: E229G (h),
V552 M (h), H606Y (h),
Q625H (h)
Table 1 continued on following page
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101 7m OCA1B/
OCA2
OCA2  c.1327G4A (V443I) — TYR: S192Y (H),
R402Q (H); OCA2:
R419Q (H); SLC45A2:
L374F (h); HPS4:
E229G (h), L443V (H),
V552 M (h), H606Y (h),
Q625H (h)
102 7m OCA1B/
OCA2
OCA2  c.79G4A (G27R) — TYR: S192Y (H);
OCA2: R305W (H),
L440F (H); SLC45A2:
L374F (H); HPS4:
H235R (H), E229G (h),
V552 M (h), H606Y (h),
Q625H (h)
103 3 OCA1B/
OCA2
OCA2  c.1951+1G4A
(IVS18+1G4A)
— TYR: S192Y (h);
SLC45A2: L374F (H)
104 4 OCA1A/1B OCA2  c.1465A4G (N489D) — OCA2: R305W (h)
105 15 OCA1B OCA2  c.1901T4A (I634N) —
106 ? OCA OCA2  c.79G4A (G27R) — TYR: S192Y (H),
R402Q (H); OCA2:
L440F (H); SLC45A2:
L374F (h)
SLC45A2 107 3m OCA1A OCA4  c.298G4A (G100S) — TYR: R402Q (h);
OCA2: IVS5-19A4G (H);
SLC45A2: H94D (H),
L374F (h)
108 Adult OCA1A OCA4  c.1164-1166delAA — TYRP1: A24T (H)
109 11 OCA1B OCA4  c.301C4T (R101C) c.1074-1077delAG TYR: P152S (H)
110 75 OCA2 OCA4  c.130G4A (G44R) c.1004T4G (M335R)
111 23 OCA2 OCA4  c.593G4A (G198D) c.1502C4A (A501D) TYR: S192Y (h);
SLC45A2: L374F (h)
112 10 OCA2 OCA4  c.834C4G (Y278X) — SLC45A2: S143R (H)
113 7 OCA OCA4 ? c.986delC c.986delC TYR: S192Y (H)
No
mutations
114 13m OCA1A —  — — HPS4: E229G (H),
L443V (H), V552 M (H),
H606Y (H), Q625H (H)
115 3 OCA2 — ? — — TYR: S192Y (H);
SLC45A2: L374F (h)
116 10 OCA2 — ? — — HPS4: E229G (h),
L443V (H), V552 M (h),
H606Y (h), Q625H (h)
117 Child OCA2 —  — — SLC45A2: L374F (h);
HPS4: E229G (h),
V552 M (h), H606Y (h),
Q625H (h)
118 4m OCA — ? — — OCA2: IVS21+18A4G
(H); SLC45A2: L374F (h);
HPS4: E229G (h),
V552 M (h), H606Y (h),
Q625H (h)
119 31 OCA —  — — OCA2: R419Q (H);
HPS1: P491R (H),
Q603R (H); HPS4:
E229G (h), L443V (H),
V552 M (h), H606Y (h),
Q625H (h)
Table 1 continued on following page
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the other allele. Extensive analysis of the OCA2 SNP
haplotype patterns in these patients indicated that, although
one or two might have partial OCA2 gene deletions, these are
unlikely to be frequent (data not shown).
TYRP1 (OCA3)
We sequenced the eight exons of the TYRP1 gene and
adjacent intron and flanking sequences (Sturm et al., 1995) in
all patients who lacked two pathologic mutations of TYR. We
observed no apparent pathologic TYRP1 mutations in any
patients, although we observed two novel variants (A24T and
R93H), both of which seem likely to constitute rare
nonpathologic polymorphisms, as they were found in patients
who had clear pathologic mutations in other genes.
SLC45A2 (MATP; OCA4)
We sequenced the seven exons of the SLC45A2 gene and
adjacent intron and flanking sequences (Newton et al., 2001)
in all patients who lacked two pathologic mutations of TYR.
We identified apparent pathologic mutations in 7 patients
(6%; Table 1). All of these patients had severe OCA, several
with a somewhat silvery sheen of their hair. In four patients,
we found two pathologic SLC45A2 mutations, and in three
patients, we found only one. Overall, we identified 12
different apparently pathologic SLC45A2 mutations, of which
11 were novel: a nonsense mutation, Y278X; eight missense
substitutions, G44R, H94D, G100S, R101C, S143R, G198D,
M335R, A501D; and two frameshifts, c.1074delAG and
c.1164delAA. In addition, we observed one missense variant
(L374F) that is a common nonpathologic polymorphism
thought to perhaps play a role in normal ethnic pigmentary
variation (Yuasa et al., 2006). The majority of SLC45A2
mutations were observed in the compound heterozygous
state; only 392delC was observed in a homozygote; no
mutation appeared to be particularly common.
HPS1, HPS4, SILV
We sequenced the 20 exons of the HPS1 gene (Oh et al.,
1996), the 13 exons of the HPS4 gene (Suzuki et al., 2002),
the 12 exons of the SILV gene (Bailin et al., 1996), and
adjacent intron and flanking sequences in all patients who
lacked two pathologic mutations of TYR. We identified no
apparent pathologic mutations of HPS1, HPS4, or SILV in any
patients, although we observed several common nonpatho-
logic polymorphisms, including HPS1 P491R and HPS4,
E229G, V552M, H606Y, Q625H (which appear to be in
perfect linkage disequilibrium), and L443V, which occurs on
the background of the HPS4 E229G/V552M/H606Y/Q625H
variant allele.
DISCUSSION
Among the 121 non-Hispanic/Latino Caucasian OCA patients
studied here, 69% had OCA1, 18% had OCA2, none had
OCA3, 6% had OCA4, and 7% had no identifiable
pathologic mutations in any of the genes studied. No patients
had undiagnosed HPS1 or HPS4, and none had mutations of
SILV, a candidate OCA gene. These findings thus indicate
that, contrary to long-standing clinical lore (King et al., 2001,
2007; King and Oetting, 2006), among Caucasian patients with
OCA, the great majority has OCA1. Virtually none have OCA3.
Among patients with OCA1, about half of the patients
genotypically have ‘‘tyrosinase-negative’’ OCA1A and about
half have OCA1B, associated with low residual tyrosinase
catalytic activity. Clinical distinction between these two
diagnostic subcategories may be difficult in Caucasian
patients, especially in patients from families with fair
complexion, and indeed accuracy of these a priori clinical
diagnoses was only 71%. Accuracy of clinical diagnoses was
especially low among very young patients, in whom
progressive pigmentation of OCA1B may not yet be evident,
and among older patients, in whom age-related lightening of
hair pigmentation may obscure the correct diagnosis.
We observed a diversity of pathologic mutations in each
gene. Nevertheless, among the patients with OCA1, 13
mutations accounted for 62% of total alleles. T373K is most
frequent overall (13.7%), which together with P81L, V275F,
G446S, and IVS2-7T4A account for 41% of total mutant TYR
alleles among Caucasian patients. Similarly, among the patients
with OCA2, 3 mutations accounted for most of the total, and
two, V443I and G27R, accounted for half. It remains
problematic that, in 17% of the OCA1 patients, 41% of the
OCA2 patients, and 43% of the OCA4 patients, we were able
to find only one pathologic mutation. These patients most likely
are compound heterozygotes for TYR alleles carrying occult
Table 1. Continued
Gene Patient Age
Clinical
diagnosis
Molecular
diagnosis Consanguinity Mutation 1 Mutation 2 Other
120 Adult OCA — ? — — TYR: S192Y (H), R402Q
(H); OCA2: R305W (H);
HPS4: E229G (h), L443V
(H), V552 M (h), H606Y
(h), Q625H (h)
121 Child OCA — ? — — HPS4: E229G, V552 M,
H606Y, Q625H (h)
(H), heterozygous; (h), homozygous
All subjects were subjected to DNA sequence analysis of the TYR (OCA1), OCA2, TYRP1 (OCA3), SLC45A2 (OCA4), HPS1, HPS4, and SILV genes. Overall,
84 (69%) patients had OCA1, 22(18%) OCA2, 0 OCA3, and 7 (6%) OCA4; 8 (7%) had no identifiable gene mutations and so could not be classified.
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mutations deep within the intervening sequences or regulatory
elements distant from the respective structural genes that were
not sequenced. Alternatively, some of these patients may have
partial gene deletions not detected by PCR-based DNA
sequencing, although heterozygosity patterns of common
intragenic SNPs suggested that such deletions are not frequent.
Interestingly, 7 of the 14 nondiagnostic TYR alleles carried the
common (q¼0.278 among Caucasians) R402Q polymorph-
ism, which results in a thermolabile tyrosinase polypeptide that
has reduced catalytic activity at 371C (Tripathi et al., 1991) and
which is very highly associated with TYR-related AROA (Fukai
et al., 1995; Hutton and Spritz, 2008). The elevated frequency
(P¼0.05) of the R402Q variant among ‘‘nondiagnostic’’ OCA1
alleles suggests that the R402Q variant (or an occult mutation
with which it is in linkage disequilibrium) might also contribute
to a more severe OCA1 phenotype in some patients.
The findings of this study are generally similar to those of a
parallel study we have carried out of USA/Canada non-
Hispanic/Latino Caucasian patients with AROA (Hutton and
Spritz, 2008), a disorder that represents clinically mild
presentations of OCA. In a series of 37 AROA patients, 60%
had pathological mutations of TYR, 14% had mutations of
OCA2, and possibly 5% had mutations of TYRP1, although it is
not certain that these last were pathologic. Among the patients
with TYR-related AROA, 95% were compound heterozygotes
for a severe OCA1-mutant allele (again, most commonly
T373K) and the common R402Q polymorphic variant.
Tomita et al. (2000) have reported a similar analysis of a
series of 80 patients with the clinical diagnosis of OCA from
Japan. These investigators found that, among those 80
patients, 47% had OCA1, 7.5% had OCA2 (Suzuki et al.,
2003), 24% had OCA4 (Inagaki et al., 2004), and 12.5% had
HPS1 (Ito et al., 2005). Although superficially similar, this
prevalence distribution in Japanese patients is in fact
significantly different from that reported here for non-
Hispanic/Latino Caucasian OCA patients (P¼2.3E-7). Never-
theless, in both Japanese and Caucasian patients, the most
prevalent form of OCA is OCA1, whereas OCA2 and OCA4
are much less frequent and OCA3 is virtually non-existent.
Our findings thus demonstrate that, among non-Hispanic/
Latino Caucasian patients with either classical OCA or
AROA, the great majority has OCA1, with lower percentages
having other types of OCA and a few remaining diagnosti-
cally indeterminate. Furthermore, although both OCA and
AROA result from a diversity of different gene mutations, for
both disease presentations a relatively limited number of
mutations account for the majority of mutant alleles. These
findings have important implications for molecular diagnostic
strategies aimed at efficient detection of mutations among
Caucasian OCA patients.
MATERIALS AND METHODS
Subjects
All study subjects were non-Hispanic/Latino Caucasians from the
USA, Canada, or northern Europe, each carrying the clinical
diagnosis of OCA, referred to the investigator for molecular
diagnostic analysis. Photographs were available for most patients,
and a number of patients were examined clinically by the
investigator. Patients with the clinical diagnoses of HPS, CHS, and
AROA were excluded. Samples were collected in accordance with
the Declaration of Helsinki Principles. This study was approved as a
no-consent study by the Combined Institutional Review Board of the
University of Colorado at Denver and Health Sciences Center, on the
grounds that it utilized only archived samples for the original
purpose for which the samples were obtained.
Molecular genetic analyses
DNA prepared from peripheral blood leukocytes was quantified
using a Nanodrop ND-1000 Spectrophotometer. For patients with
less than 30 ng ml1 DNA, whole-genome amplification was
performed using the QIAGEN REPLI-g Midi Kit and the products
were quantified using the Invitrogen Quant-iT PicoGreen dsDNA
Quantification Kit.
For each patient, amplicons containing each exon and adjacent
flanking regions of the TYR, OCA2 (P), TYRP1, and SLC45A2 (MATP)
genes, the 50 promoter regions of TYR (1,555 nt, excluding a simple
sequence repeat from nt 88549828–88550258) and OCA2, and a
conserved 647-bp segment located 8,989 bp upstream from the TYR
major mRNA 50 terminus that may represent a locus control region
(Regales et al., 2003) were amplified by touchdown PCR for DNA
sequencing. For patients with no apparent pathological mutations in
any of these genes, amplicons containing each exon of the HPS1,
HPS4, and SILV genes were then amplified for sequencing. PCRs
were carried out in 25 ml volumes containing 30 ng DNA, 5 pmol of
each primer (listed in Supplementary Table 1), 2.5 ml of 10 PCR
buffer, 1.5 mM MgCl2, 1.25 M betaine, 0.2 mM Applied Biosystems
(ABI; Foster City, CA) GeneAmp dNTP Blend, and 2.0 U Invitrogen
Platinum Taq DNA Polymerase. For most amplicons, DNA was
denatured at 941C for 10 minutes followed by 15 cycles of
denaturation at 941C for 30 seconds, annealing from 63 to 561C
for 45 seconds decreasing 0.51C each cycle, and elongation at 721C
for 1 minute, followed by an additional 25 cycles of denaturation at
941C for 30 seconds, annealing at 561C for 45 seconds, and
elongation at 721C for 1 minute, followed by a final extension at
721C for 10 minutes in an ABI 9600 or 9700 thermocycler. For TYR
exon 4 the annealing range was further decreased to 541C by adding
four more cycles at the initial stage and by decreasing the annealing
temperature of the following 25 cycles to 541C.
Codon and nucleotide enumeration is referent to TYR transcript
ENSG00000077498, OCA2 transcript ENST00000354638, TYPR1
transcript ENST00000381142 (the longest transcript, which includes
all others), SLC45A2 (OCA4) transcript ENST00000382102, HPS1
transcript ENST00000359632, HPS4 transcript ENST00000336873,
and SILV transcript ENST00000358822. Mutation nomenclature
conforms to standard convention (Antonarakis and the Nomencla-
ture Working Group, 1998).
DNA sequencing
PCR products were purified either using the QIAGEN QIAquick PCR
Purification Kit or by a modified shrimp alkaline phosphatase/
exonuclease I method, in which for every 5 ml of PCR product, we
added 2 ml shrimp alkaline phosphatase, mixed for 1 min, added 1ml
of exonuclease I, mixed again for 1 minute and incubated samples at
371C for 15 minutes and then at 801C for 15 minutes.
A total of 100 ng DNA of each PCR product was sent to the
University of Colorado Cancer Center DNA Sequencing and
www.jidonline.org 2449
SM Hutton and RA Spritz
Genetics of Oculocutaneous Albinism in Caucasians
Analysis Core and sequenced using an ABI 3730 DNA Analyzer.
Analyses of DNA sequences were carried out using Gene Codes
Sequencher software. Evolutionary conservation of variant amino-
acid residues was evaluated by alignment of orthologous protein
sequences from human, chimpanzee (Pan troglodytes), macaque
(Macaca mulatta), dog (Canis familiaris), mouse (Mus musculus), rat
(Rattus norvegicus), and chicken (Gallus gallus) obtained from the
National Center for Biotechnology Information (http://www.ncbi.
nlm.nih.gov/) or Ensembl (http://www.ensembl.org).
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